Stéphane Dalle

8PUBLICATIONS
117CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cellular immunologyTumour immunologyRadiation therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 29, 2026
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.

|Jan 08, 2025
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma.

Elisa Gobbini, Margaux Hubert, Anne-Claire Doffin

|Dec 04, 2024
Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients.

Fanny Beltzung, Marie Beylot-Barry, Maxime Battistella

|Jun 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network.

Robin Zagala, Stephane Dalle, Marie Beylot-Barry

|Apr 02, 2024
NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer.

Guilhem Lalle, Raphaëlle Lautraite, Khaled Bouherrou

|Apr 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

James Larkin, Michele Del Vecchio, Mario Mandalá

Pageof 2

Frequent Collaborators

2 joint publications

Marie Beylot-Barry

2 joint publications

Luc Thomas

2 joint publications

Julie Caramel

2 joint publications

Maxime Battistella